he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看信源URL
- 2022-05-10少儿癫痫病的后期症状和病因有哪些
- 2022-04-252013年国际抗癫痫联合会抗癫痫解毒使用指南
- 月经期间能喝茶吗? 女性月经期间能喝茶吗?
- 超声造影“揪出”隐藏在肝脏内的定时
- 药学版元宵灯谜 看你能猜对几个问题
- 月经性癫痫患者妊娠期癫痫控制更好
- 检测和监测老龄化症状有新的工具
- 癫痫治疗障碍仍难以克服
- 癫痫猝死:凶手是谁?
- JGH: 依洛西巴特(Elobixibat)影响慢性便秘患者血清、粪便胆汁酸水平和便秘症状
- 被WHO推荐,IVD国产替代品在结核病诊断领域取得了新的成果
- 癫痫发作对中风患者静脉溶栓的长期转移有效
- 泡温泉时不能忽视的事情
- 常见妇科炎症的相关问答
- Exeltis旗下Slynd药片获FDA批准成为首款只含孕酮的避孕药
- B正确打开超检单的方法!医生如何判断疾病?
- 喝茶对白癜风有什么影响?
- 癫痫患者停药问题解决了吗?最新的预测模型已经发布!
- 囊肿能自愈吗?
- Medpage Today:不同类型的抗癫痫药物更有利
- 膀胱炎的症状 有四种症状。小心膀胱炎在路上
- 月经期间要注意 有些药物和食物不能食用
- 慢性炎症状 关注男性健康
- 2015第31届国际癫痫大会(IEC)
- 根治性切除保留神经:可提高术后尿控率
- 特发性癫痫大发作药物治疗的首选
- 预测癫痫患者再入院风险
- 治疗白癜风的方法 牢记这些治疗白癜风更省钱
- 三庚酸酯可治疗1型转运体缺陷综合征
- 病人癫痫病比较好的方法是什么
- 癫痫病的用药方法有哪些常用方式
- 小儿帕金森氏症的早期症状 帕金森氏症的原因
- 治疗腹型癫痫病能够多少钱
- 大脑或共存两种短时记忆系统
- 怎么准确诊疗癫痫病?
- 神经胶质瘤释放的谷氨酸盐可诱发帕金森氏症
- 癫痫病治疗后必需多久能康复
- Neurology:颅脑损伤增加迟发性癫痫发生风险,极高损伤频率、重伤、老年人尤甚
- 怎么样对原发性癫痫病进行化疗
- 长期酗酒 需警惕 Marchiafa-Bignami 小儿
- 小儿癫痫成因的常见成因有哪些
- 【用药问答】治疗癫痫大发作和上都发作的药物?